*Disseminated on Behalf of Liminatus Pharma, Inc.
Market Crux Announces Coverage On Liminatus Pharma, Inc. (Nasdaq: LIMN) Starting This Morning—Friday, August 15, 2025
Here's Why…
Recently Announced Its Reviewing A Digital Asset Arm That Could Secure Up To $500M While Operating Independently From Core Programs
Less Than 5M Shares In The Float Could Set The Stage For Big Swing Potential If Demand Starts To Shift
Multiple Triple-Digit Percentage Swings In 2025, Including (Approx.)
369%, 151%, And 116% Overnight Moves
Consider Starting Your Research On (Nasdaq: LIMN) This Morning
August 15, 2025 At The Bell | See Why (Nasdaq: LIMN) Just Hit Our Early Radar This Morning Dear Reader, If you haven't pulled up (Nasdaq: LIMN) yet, this may be the time. Every so often in biotechnology, a company emerges that refuses to follow the script. Most stick to a single lane — advance a promising therapy, secure conventional financing, and hope the runway holds. But Liminatus Pharma, Inc. (Nasdaq: LIMN) is taking a different route, one that blends cutting-edge cancer research with a capital strategy rarely seen in the industry. Funding the Future Like No Other BioPharma
While the company's science is compelling, what immediately sets (Nasdaq: LIMN) apart is how it's thinking about financing the journey ahead. In July 2025, the company began a strategic review to evaluate the potential formation of a digital asset arm through a prospective subsidiary, which could seek to raise up to approximately $500M via private placements, convertible instruments, and equity lines. The move is designed to operate independently from its core clinical programs, providing maximum flexibility to pursue long-term goals while aiming to minimize dilution. It's a capital innovation approach that signals leadership is planning well beyond the next trial. (Nasdaq: LIMN)'s Recent Momentum
This blend of scientific and fiscal strategy comes against the backdrop of a low float — under 5M shares— which could set the stage for significant swing potential if demand starts to shift. And recent history shows exactly what that can mean for (Nasdaq: LIMN): - June 4, 2025: from $5.30 to $24.88 — approximate 369% overnight move
- June 3–4, 2025: from $5.05 to $12.71 — approximate 151% overnight move
- June 11–12, 2025: from $10.80 to $23.38 — approximate 116% overnight move
- June 20–23, 2025: from $12.87 to $22.13 — approximate 71% move from Friday to Monday
- July 9–10, 2025: from $5.05 to $7.45 — approximate 47% overnight move
In a market where sentiment can turn in hours, LIMN has repeatedly demonstrated the potential for rapid, attention-grabbing percentage swings when headlines land. The Intersection of Science and Strategy
Headquartered in La Palma, California, Liminatus operates in one of the most competitive — and potentially transformative — areas of medicine: cancer immunotherapy. Its lead program, IBA101, targets a key immune checkpoint that cancer cells exploit to evade the body's defenses. Cracking the Code on Cancer's "Do Not Eat Me" Signal
CD47 acts as a molecular shield — the "do not eat me" signal — preventing macrophages from attacking cancer cells. Blocking CD47 removes that shield, allowing the immune system to identify and destroy tumors. The problem with first-generation CD47 inhibitors was their tendency to bind indiscriminately to red blood cells and platelets, leading to anemia and thrombocytopenia. How LIMN's Next-Gen Antibody Changes the Rules
IBA101 was engineered to preferentially bind to immune cells, not red blood cells or platelets. In preclinical primate studies, this design eliminated the blood safety concerns that plagued earlier drugs, even at higher doses. When paired with PD-1 or PD-L1 inhibitors in animal models, IBA101 achieved complete tumor inhibition and regression — data that points to its potential in combination therapy. A $123.3B Combination Therapy Market in Sight
The PD-1/PD-L1 therapy market was valued at $49.5B in 2023 and is projected to grow over 140% to reach $123.3B by 2033. Analysts expect CD47 inhibitors to enter this market primarily as combination treatments, potentially capturing 10–20% by 2030 and expanding rapidly from there. For a company with a differentiated approach in this field, the addressable market is significant. Pipeline Progress Already Underway
Liminatus has completed key IND-enabling work, including CMC development and GLP-compliant toxicity studies in monkeys. The company plans to file IND applications with both the U.S. FDA and Korea's MFDS in the second half of 2026, with Phase I human trials expected to begin in early 2027 in collaboration with Samsung Medical Center in Seoul. Positioned Between Two Expanding Global Markets
Beyond cancer immunotherapy/CD47 therapeutics — projected to reach $106.7B by 2032 — Liminatus also has potential exposure to the artificial blood/oxygen carrier market, estimated at $15.4B by 2027, with applications in trauma care, military medicine, space exploration, and disaster response. Why the Next 24 Months Could Define LIMN
With a differentiated therapy targeting a validated checkpoint, a clear regulatory timeline, a bold funding model under review, and a share structure that could magnify market reactions, Liminatus Pharma (Nasdaq: LIMN) is positioned for a period of significant developments. Over this span, the company plans to submit IND applications for IBA101 in late 2026 and initiate Phase I human trials in early 2027 in collaboration with Samsung Medical Center. In parallel, the company is reviewing the creation of a $500M digital asset investment arm — a move that could shape how future clinical milestones are financed. And with a low float under 5M shares at times, each headline during this period has the potential to spark amplified market moves. Coverage is now officially underway on Liminatus Pharma, Inc. (Nasdaq: LIMN). Expect updates as each milestone approaches. 7 Reasons Why (Nasdaq: LIMN) Is Topping Our Watchlist
This Morning—Friday, August 15, 2025
1. Limited Float: with less than 5M shares listed in its float, (Nasdaq: LIMN) could have the potential to witness significant swings if demand begins to shift. 2. Recent Momentum: (Nasdaq: LIMN) has showcased multiple triple-digit percentage moves in 2025, including approx. 369%, 151%, and 116% overnight swings. 3. $500M Funding Vision: the company is reviewing the creation of a digital asset arm that could secure up to $500M while operating independently from core clinical programs. 4. Next-Gen Science: (Nasdaq: LIMN) is advancing IBA101, a next-generation CD47 antibody designed to avoid red blood cell and platelet binding that hindered earlier approaches. 5. Combination Therapy Potential: analysts project the PD-1/PD-L1 market to reach $123.3B by 2033, with CD47 inhibitors like (Nasdaq: LIMN)'s candidate expected to gain a significant foothold through combination use. 6. Advancing Toward Trials: IND-enabling studies for (Nasdaq: LIMN) are complete, with regulatory filings planned for late 2026 and Phase I human trials anticipated in early 2027. 7. Dual Market Exposure: in addition to cancer immunotherapy, (Nasdaq: LIMN) has potential reach into the artificial blood/oxygen carrier space, projected at $15.4B by 2027. With these potential catalysts aligned, (Nasdaq: LIMN) is moving into a period where critical decisions, milestone announcements, and market-moving headlines could converge in rapid succession. The setup we're looking at heading into tomorrow is the kind that can put a profile front and center on our watchlist. Consider Starting Your Research On (Nasdaq: LIMN) This Morning
With a float of less than 5M shares, a history of multiple triple-digit percentage moves in 2025, and a $500M funding plan under review, Liminatus Pharma (Nasdaq: LIMN) stands out as a profile blending distinctive science with strategic foresight. The company's next-generation CD47 program, IBA101, is designed to address limitations of earlier approaches and is positioned within a combination therapy market projected to exceed $123B by 2033.
With IND submissions planned for late 2026, human trials anticipated in early 2027, and potential exposure to two expanding healthcare markets, the next chapters for (Nasdaq: LIMN) will be worth close attention. We have all eyes on (Nasdaq: LIMN) today. Consider starting your research (Nasdaq: LIMN) while it's still early. My next update could be hitting at any moment—so keep an eye out for it.
Sincerely,
Gary Silver
Managing Editor,
Market Crux | 
